This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Von Willebrand's disease (comparison with the features of Haemophilia A and Haemophilia B)

Authoring team

Comparison between the clinical and laboratory features found in Haemophilia A, Haemophilia B and Von Willebrand's disease

Haemophilia A

Haemophilia B

Von Willebrand's disease

Mode of inheritance

X-linked

X-linked

Autosomal Dominant (incomplete)

Main sites of Bleeding

muscle, joints, following trauma or post operation

muscle, joints, following trauma or post operation

skin cuts, mucous membranes, following trauma and post operation

platelets

normal platelet count

normal platelet count

normal platelet count

bleeding time

normal

normal

prolongation of bleeding time

prothrombin time

normal

normal

normal

Activated partial thromboplastin time (APTT)

prolonged

prolonged

prolonged

von Willebrand's Factor

normal

normal

reduced levels

factor VIII

low levels

normal

low levels - vWF is the carrier molecule for factor VIII thus preventing it from premature destruction - this property explains the reduced factor VIII levels found in von Willebrands disease

factor IX

normal

low levels

low levels

ristocetin-induced platelet aggregation

normal

normal

ristocetin fails to induce platelet aggregation in von Willebrand's patients because of lack of vWF:R - a cofactor for ristocetin


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.